Your browser is no longer supported. Please, upgrade your browser.
XYN Xynomic Pharmaceuticals Holdings, Inc. daily Stock Chart
Xynomic Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own49.60% Shs Outstand39.07M Perf Week-10.06%
Market Cap115.26M Forward P/E- EPS next Y- Insider Trans- Shs Float9.49M Perf Month-12.20%
Income-0.60M PEG- EPS next Q- Inst Own1.40% Short Float0.01% Perf Quarter-72.01%
Sales- P/S- EPS this Y-67.30% Inst Trans- Short Ratio0.01 Perf Half Y-71.22%
Book/sh3.09 P/B0.95 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.00 P/C- EPS next 5Y- ROE- 52W Range2.29 - 11.00 Perf YTD-71.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.18% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low28.82% ATR0.43
Employees25 Current Ratio0.00 Sales Q/Q- Oper. Margin- RSI (14)39.14 Volatility6.54% 9.98%
OptionableNo Debt/Eq0.06 EPS Q/Q128.60% Profit Margin- Rel Volume0.58 Prev Close2.95
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume48.47K Price2.95
Recom- SMA20-10.94% SMA50-31.11% SMA200-66.17% Volume0 Change0.00%
Jun-20-19 10:54AM  Read This Before Selling Xynomic Pharmaceuticals Holdings, Inc. (NASDAQ:XYN) Shares Simply Wall St.
Jun-12-19 12:38PM  Xynomic Pharma Pops Higher After FDA Update Benzinga +10.95%
10:00AM  Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer GlobeNewswire
Jun-06-19 12:30PM  Xynomic Dosed First Patient in Phase 1/2 Lymphoma Trial GlobeNewswire -6.56%
May-21-19 04:30PM  Xynomic Pharma To Present Long-Term Follow Up Data Showing Abexinostat, Combined with Pazopanib, has Durable Responses in Patients with Pre-Treated Kidney Cancer GlobeNewswire
Xynomic Pharmaceuticals Holdings, Inc. a biopharmaceutical company, focuses on in-licensing, developing, and commercializing oncology drug candidates in China, the United States, and internationally. The company's pipeline primarily consists of three drug candidates, abexinostat, XP-105, and XP-102. Its lead drug candidate abexinostat is in pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin's lymphoma (as a single agent). The company's other clinical stage drug candidate XP-105 (BI 860585) is a Phase 2 ready, ATP-competitive mTORC1/2 inhibitor against solid tumors; and pre-clinical oncology drug candidate XP-102 (BI 882370) is a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.